Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 12;13(1):17.
doi: 10.1186/s12348-023-00339-0.

Ocular side effects of Trametinib and Dabrafenib: a case report

Bilge Tarım  1 , Meltem Kılıç  2
Affiliations

Ocular side effects of Trametinib and Dabrafenib: a case report

Bilge Tarım et al. J Ophthalmic Inflamm Infect. .

Abstract

A 53-year-old man who has stage 4 non-small cell lung carcinoma and treated with Dabrafenib-Trametinib combination chemotherapy; presented with decreased bilateral visual acuity. We checked out slit lamp examination, fundoscopy, optical coherence tomography and fundus fluorescein angiography. In slit lamp biomicroscopy; bilateral posterior synechiae, granulomatous keratic precipitates and + 4 cells in the anterior chamber were detected. Cystoid macular edema and subretinal fluid accumulation were revealed in optical coherence tomography. Dabrafenib and Trametinib treatments were discontinued and systemic methylprednisolone, topical corticosteroid and topical cyclopentolate were started. His best corrected visual acuity was increased from counting fingers from 2 m to 0,9 bilaterally and cystoid macular edema and serous retinal detachment were completely regressed as a result of systemic and topical corticosteroid treatment.

Keywords: Cystoid macular edema; Dabrafenib; Serous retinal detachment; Trametinib; Uveitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Anterior segment photographs of the right and left eyes at presentation
Fig. 2
Fig. 2
02.09.2021 (At presentation): BCVA (counting fingers from 2 m/counting fingers from 2 m)
Fig. 3
Fig. 3
03.09.2021: BCVA (0.1/0.1)
Fig. 4
Fig. 4
06.09.2021: BCVA (0.4/0.4)
Fig. 5
Fig. 5
09.09.2021: BCVA (0.4/0.7)
Fig. 6
Fig. 6
16.09.2021: BCVA (0.8/0.8)
Fig. 7
Fig. 7
30.09.2021: BCVA (0.9/0.9)
Fig. 8
Fig. 8
07.10.2021: BCVA (0.4/0.4)
Fig. 9
Fig. 9
21.10.21: BVCA (0.7/0.7)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–42. doi: 10.1097/JTO.0000000000000663. - DOI - PubMed
    1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244e285. doi: 10.1097/JTO.0b013e318206a221. - DOI - PMC - PubMed
    1. Leonetti A, Facchinetti F, Rossi G, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018;66:82e94. doi: 10.1016/j.ctrv.2018.04.006. - DOI - PubMed
    1. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984e993. - PMC - PubMed
    1. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855e867. doi: 10.1016/S0092-8674(04)00215-6. - DOI - PubMed

LinkOut - more resources